← Molina Healthcare overview

Molina Healthcare vs Centene: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Molina Healthcare Inc (MOH)

Q3 2026
▼3▲1

Molina beats Q2, raises guidance, but membership and ACA cuts weigh

  • Revenue decline and membership loss Molina's Q1 and Q2 revenues fell year over year, with Q2 down 4.8% to $10.9 billion and total membership dropping 14.3% to about 4.9 million. Fewer customers mean less premium income, which pressures future profits and the stock price.

    Shows the core demand problem that is dragging on MOH's price.

  • Q2 earnings beat and raised 2026 guidance Molina beat Q2 earnings estimates by 10.2% and raised its full-year 2026 adjusted EPS guidance to at least $5.25. This signals cost control is working and gives investors more confidence in future profits, which supports the stock.

    This is the main positive force behind MOH's price right now.

  • ACA business pullback starting 2027 Molina plans to sharply cut its Affordable Care Act plans from 2027, limiting them to six states and lowering premiums. This reduces future revenue and shows management sees ACA as unprofitable, which weighs on long-term growth expectations.

    A major strategic shift that changes Molina's future revenue mix and risk.

  • High medical care ratio and tariff risk Molina's medical care ratio rose to 92.2%, meaning it spent more of each premium dollar on patient care, and shares fell about 11% despite the earnings beat. New tariffs on generic drug imports could raise future costs, adding pressure.

    Explains why the stock dropped even after good earnings and highlights a new cost risk.

July 2026
▼3▲1

Molina beats Q2, raises guidance, but membership and ACA cuts weigh

  • Revenue decline and membership loss Molina's Q1 and Q2 revenues fell year over year, with Q2 down 4.8% to $10.9 billion and total membership dropping 14.3% to about 4.9 million. Fewer customers mean less premium income, which pressures future profits and the stock price.

    Shows the core demand problem that is dragging on MOH's price.

  • Q2 earnings beat and raised 2026 guidance Molina beat Q2 earnings estimates by 10.2% and raised its full-year 2026 adjusted EPS guidance to at least $5.25. This signals cost control is working and gives investors more confidence in future profits, which supports the stock.

    This is the main positive force behind MOH's price right now.

  • ACA business pullback starting 2027 Molina plans to sharply cut its Affordable Care Act plans from 2027, limiting them to six states and lowering premiums. This reduces future revenue and shows management sees ACA as unprofitable, which weighs on long-term growth expectations.

    A major strategic shift that changes Molina's future revenue mix and risk.

  • High medical care ratio and tariff risk Molina's medical care ratio rose to 92.2%, meaning it spent more of each premium dollar on patient care, and shares fell about 11% despite the earnings beat. New tariffs on generic drug imports could raise future costs, adding pressure.

    Explains why the stock dropped even after good earnings and highlights a new cost risk.

Latest
▼3▲1

Molina beats Q2, raises guidance, but membership and ACA cuts weigh

  • Revenue decline and membership loss Molina's Q1 and Q2 revenues fell year over year, with Q2 down 4.8% to $10.9 billion and total membership dropping 14.3% to about 4.9 million. Fewer customers mean less premium income, which pressures future profits and the stock price.

    Shows the core demand problem that is dragging on MOH's price.

  • Q2 earnings beat and raised 2026 guidance Molina beat Q2 earnings estimates by 10.2% and raised its full-year 2026 adjusted EPS guidance to at least $5.25. This signals cost control is working and gives investors more confidence in future profits, which supports the stock.

    This is the main positive force behind MOH's price right now.

  • ACA business pullback starting 2027 Molina plans to sharply cut its Affordable Care Act plans from 2027, limiting them to six states and lowering premiums. This reduces future revenue and shows management sees ACA as unprofitable, which weighs on long-term growth expectations.

    A major strategic shift that changes Molina's future revenue mix and risk.

  • High medical care ratio and tariff risk Molina's medical care ratio rose to 92.2%, meaning it spent more of each premium dollar on patient care, and shares fell about 11% despite the earnings beat. New tariffs on generic drug imports could raise future costs, adding pressure.

    Explains why the stock dropped even after good earnings and highlights a new cost risk.

Centene Corp (CNC)

Q3 2026
▲2▼1

Centene's profit recovery accelerates as costs ease and guidance jumps

  • Q2 earnings blow past estimates, 2026 profit outlook raised sharply Centene reported Q2 adjusted EPS of $2.51, crushing the $1.09 consensus, and raised full-year 2026 profit guidance to over $4.80 from $3.40. The medical loss ratio improved to 89.6% from 93%, showing costs are finally under control. This directly boosts the stock because it signals a faster-than-expected turnaround.

    This is the period's biggest new event and the main reason CNC is moving.

  • Medical cost trend stabilizes, easing two-year industry squeeze Oakmark and other funds noted that the unprecedented spike in medical costs is stabilizing or decelerating. Combined with better pricing and Centene's expense cuts, this points to a multi-year earnings recovery. For investors, it means the worst of the margin pressure may be over, supporting a higher stock price.

    Explains the fundamental force behind the profit rebound and why investors are more optimistic.

  • Trump administration ends Medicare Part D subsidy, raising 2027 premiums The administration is ending a $3.6 billion subsidy that helped insurers keep Part D premiums low. Three out of four enrollees will see higher monthly premiums in 2027, and Centene, as a top Part D insurer, faces reduced government payments and potential membership loss. This is a real counterweight that could pressure future profits.

    It is the main negative development this period and a genuine risk to the bullish story.

July 2026
▲2▼1

Centene's profit recovery accelerates as costs ease and guidance jumps

  • Q2 earnings blow past estimates, 2026 profit outlook raised sharply Centene reported Q2 adjusted EPS of $2.51, crushing the $1.09 consensus, and raised full-year 2026 profit guidance to over $4.80 from $3.40. The medical loss ratio improved to 89.6% from 93%, showing costs are finally under control. This directly boosts the stock because it signals a faster-than-expected turnaround.

    This is the period's biggest new event and the main reason CNC is moving.

  • Medical cost trend stabilizes, easing two-year industry squeeze Oakmark and other funds noted that the unprecedented spike in medical costs is stabilizing or decelerating. Combined with better pricing and Centene's expense cuts, this points to a multi-year earnings recovery. For investors, it means the worst of the margin pressure may be over, supporting a higher stock price.

    Explains the fundamental force behind the profit rebound and why investors are more optimistic.

  • Trump administration ends Medicare Part D subsidy, raising 2027 premiums The administration is ending a $3.6 billion subsidy that helped insurers keep Part D premiums low. Three out of four enrollees will see higher monthly premiums in 2027, and Centene, as a top Part D insurer, faces reduced government payments and potential membership loss. This is a real counterweight that could pressure future profits.

    It is the main negative development this period and a genuine risk to the bullish story.

Latest
▲2▼1

Centene's profit recovery accelerates as costs ease and guidance jumps

  • Q2 earnings blow past estimates, 2026 profit outlook raised sharply Centene reported Q2 adjusted EPS of $2.51, crushing the $1.09 consensus, and raised full-year 2026 profit guidance to over $4.80 from $3.40. The medical loss ratio improved to 89.6% from 93%, showing costs are finally under control. This directly boosts the stock because it signals a faster-than-expected turnaround.

    This is the period's biggest new event and the main reason CNC is moving.

  • Medical cost trend stabilizes, easing two-year industry squeeze Oakmark and other funds noted that the unprecedented spike in medical costs is stabilizing or decelerating. Combined with better pricing and Centene's expense cuts, this points to a multi-year earnings recovery. For investors, it means the worst of the margin pressure may be over, supporting a higher stock price.

    Explains the fundamental force behind the profit rebound and why investors are more optimistic.

  • Trump administration ends Medicare Part D subsidy, raising 2027 premiums The administration is ending a $3.6 billion subsidy that helped insurers keep Part D premiums low. Three out of four enrollees will see higher monthly premiums in 2027, and Centene, as a top Part D insurer, faces reduced government payments and potential membership loss. This is a real counterweight that could pressure future profits.

    It is the main negative development this period and a genuine risk to the bullish story.

Q2 2026
▲2▼2

Centene cuts costs, raises guidance, and secures Medicaid renewal

  • Buyouts and layoffs signal membership decline Centene launched buyouts for most of its 61,000 employees and warned of layoffs due to sharp membership declines in Medicaid and ACA. This cost-cutting reflects a shrinking business, which pressures the stock as investors worry about future revenue.

    This is a major new event that directly affects Centene's cost structure and signals underlying membership weakness.

  • UBS says AI gains may be competed away for insurers UBS analysts argue that AI efficiency gains for insurers like Centene are easily copied and will be competed away through pricing, limiting margin expansion. This tempers hopes that AI will significantly boost profits, weighing on the stock.

    This new analyst view challenges the bullish AI narrative for Centene and highlights a competitive risk.

  • Centene raises 2026 EPS guidance on strong Q1 Centene raised its 2026 adjusted EPS guidance to over $3.40 after Q1 EPS rose 16.2% to $3.37. Premium revenues grew 5.1% and Medicaid margin improved, showing better cost control and profitability, which supports a higher stock price.

    This is a new positive development that directly boosts earnings expectations and investor confidence.

  • Illinois Medicaid contract renewal secures revenue Centene's Meridian Health Plan won a four-year renewal for Illinois Medicaid, covering over 596,000 members. This preserves a steady stream of premium revenue and improves long-term earnings visibility, a positive for the stock.

    This new contract renewal reduces uncertainty and locks in a significant revenue source.

June 2026
▲2▼2

Centene cuts costs, raises guidance, and secures Medicaid renewal

  • Buyouts and layoffs signal membership decline Centene launched buyouts for most of its 61,000 employees and warned of layoffs due to sharp membership declines in Medicaid and ACA. This cost-cutting reflects a shrinking business, which pressures the stock as investors worry about future revenue.

    This is a major new event that directly affects Centene's cost structure and signals underlying membership weakness.

  • UBS says AI gains may be competed away for insurers UBS analysts argue that AI efficiency gains for insurers like Centene are easily copied and will be competed away through pricing, limiting margin expansion. This tempers hopes that AI will significantly boost profits, weighing on the stock.

    This new analyst view challenges the bullish AI narrative for Centene and highlights a competitive risk.

  • Centene raises 2026 EPS guidance on strong Q1 Centene raised its 2026 adjusted EPS guidance to over $3.40 after Q1 EPS rose 16.2% to $3.37. Premium revenues grew 5.1% and Medicaid margin improved, showing better cost control and profitability, which supports a higher stock price.

    This is a new positive development that directly boosts earnings expectations and investor confidence.

  • Illinois Medicaid contract renewal secures revenue Centene's Meridian Health Plan won a four-year renewal for Illinois Medicaid, covering over 596,000 members. This preserves a steady stream of premium revenue and improves long-term earnings visibility, a positive for the stock.

    This new contract renewal reduces uncertainty and locks in a significant revenue source.

▲2▼2

Centene cuts costs, raises guidance, and secures Medicaid renewal

  • Buyouts and layoffs signal membership decline Centene launched buyouts for most of its 61,000 employees and warned of layoffs due to sharp membership declines in Medicaid and ACA. This cost-cutting reflects a shrinking business, which pressures the stock as investors worry about future revenue.

    This is a major new event that directly affects Centene's cost structure and signals underlying membership weakness.

  • UBS says AI gains may be competed away for insurers UBS analysts argue that AI efficiency gains for insurers like Centene are easily copied and will be competed away through pricing, limiting margin expansion. This tempers hopes that AI will significantly boost profits, weighing on the stock.

    This new analyst view challenges the bullish AI narrative for Centene and highlights a competitive risk.

  • Centene raises 2026 EPS guidance on strong Q1 Centene raised its 2026 adjusted EPS guidance to over $3.40 after Q1 EPS rose 16.2% to $3.37. Premium revenues grew 5.1% and Medicaid margin improved, showing better cost control and profitability, which supports a higher stock price.

    This is a new positive development that directly boosts earnings expectations and investor confidence.

  • Illinois Medicaid contract renewal secures revenue Centene's Meridian Health Plan won a four-year renewal for Illinois Medicaid, covering over 596,000 members. This preserves a steady stream of premium revenue and improves long-term earnings visibility, a positive for the stock.

    This new contract renewal reduces uncertainty and locks in a significant revenue source.

© 2026 MarketIVWhy